Plasmid DNA Nanoparticles for Nonviral Oral Gene Therapy

Cited 0 time in webofscience Cited 0 time in scopus
  • Hit : 49
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorShahriar, S. M. Shatilko
dc.contributor.authorAn, Jeong Manko
dc.contributor.authorHasan, Mohammad Nazmulko
dc.contributor.authorSurwase, Sachin S.ko
dc.contributor.authorKim, Yeu-Chunko
dc.contributor.authorLee, Dong Yunko
dc.contributor.authorCho, Sungpilko
dc.contributor.authorLee, Yong-Kyuko
dc.date.accessioned2021-07-13T05:30:36Z-
dc.date.available2021-07-13T05:30:36Z-
dc.date.created2021-07-13-
dc.date.created2021-07-13-
dc.date.issued2021-06-
dc.identifier.citationNANO LETTERS, v.21, no.11, pp.4666 - 4675-
dc.identifier.issn1530-6984-
dc.identifier.urihttp://hdl.handle.net/10203/286566-
dc.description.abstractHerein, a bile acid-inspired triple padlock oral gene delivery platform is developed, facilitating the protection of the therapeutic gene from gastrointestinal degradation, selective intestinal accumulation through a bile acid-specific transporter, and transportation of pDNA NPs through the enterohepatic recycling system. This nonviral oral gene delivery nanoparticle exhibits excellent gene expression kinetics in in vitro, in vivo, and ex vivo studies. A single oral dose leads to maintaining normoglycemia for up to 7 days in three different diabetes mouse models and 14 days in diabetic monkeys. Also, the optimized dosage form can reduce nonfast blood glucose levels and hemoglobin A1C within a normal range from the last stage diabetes conditions with a reduction of weight gain from changes of food uptake behavior after treatment once weekly for 20 weeks. Taken together, the current findings could improve the current painful treatment experience of diabetics and thus improve their quality of life.-
dc.languageEnglish-
dc.publisherAMER CHEMICAL SOC-
dc.titlePlasmid DNA Nanoparticles for Nonviral Oral Gene Therapy-
dc.typeArticle-
dc.identifier.wosid000662078500020-
dc.identifier.scopusid2-s2.0-85108020682-
dc.type.rimsART-
dc.citation.volume21-
dc.citation.issue11-
dc.citation.beginningpage4666-
dc.citation.endingpage4675-
dc.citation.publicationnameNANO LETTERS-
dc.identifier.doi10.1021/acs.nanolett.1c00832-
dc.contributor.localauthorKim, Yeu-Chun-
dc.contributor.nonIdAuthorShahriar, S. M. Shatil-
dc.contributor.nonIdAuthorAn, Jeong Man-
dc.contributor.nonIdAuthorHasan, Mohammad Nazmul-
dc.contributor.nonIdAuthorLee, Dong Yun-
dc.contributor.nonIdAuthorCho, Sungpil-
dc.contributor.nonIdAuthorLee, Yong-Kyu-
dc.description.isOpenAccessN-
dc.type.journalArticleArticle-
dc.subject.keywordAuthororal delivery-
dc.subject.keywordAuthorgene therapy-
dc.subject.keywordAuthordiabetes-
dc.subject.keywordAuthorglucagon-like peptide 1-
dc.subject.keywordAuthorbile acids-
dc.subject.keywordAuthorprotein replacement therapy-
dc.subject.keywordPlusGLUCAGON-LIKE PEPTIDE-1-
dc.subject.keywordPlusGLP-1 RECEPTOR-
dc.subject.keywordPlusRELEASE-
Appears in Collection
CBE-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0